PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow

Microvascular Research

Volumn 84, Issue 1, 2012, Pages 44-54

  Li, Xiang Dong ^a   Cheng, Yu Tong ^b   Yang, Yue Jin ^a   Meng, Xian Min ^a   Zhao, Jing Lin ^a   Zhang, Hai Tao ^a   Wu, Yong Jian ^a   You, Shi Jie ^a   Wu, Yi Ling ^c  

^a FUWAI HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c The Integration of Traditional and Western Medical Research Academy of Hebei Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CREATINE KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N(G) NITROARGININE; PADGEM PROTEIN; PROTEIN BCL 2; SERINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EXPERIMENTAL PIG; HEART HEMODYNAMICS; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART PROTECTION; ISCHEMIC PRECONDITIONING; NO REFLOW PHENOMENON; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPERFUSION INJURY; UPREGULATION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEMODYNAMICS; ISCHEMIC PRECONDITIONING; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; NO-REFLOW PHENOMENON; PHOSPHORYLATION; SWINE; SWINE, MINIATURE;

EID: 84861532374     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2012.04.002     Document Type: Article

References (50)

1. Bauer P.M., Fulton D., Boo Y.C., Sorescu G.P., Kemp B.E., Jo H., Sessa W.C. Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J. Biol. Chem. 2003, 278(17):14841-14849.
2. Bekkers S.C., Yazdani S.K., Virmani R., Waltenberger J. Microvascular obstruction: underlying pathophysiology and clinical diagnosis. J. Am. Coll. Cardiol. 2010, 55(16):1649-1660.
3. Bellis A., Castaldo D., Trimarco V., Monti M.G., Chivasso P., Sadoshima J., Trimarco B., Morisco C. Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler. Thromb. Vasc. Biol. 2009, 29(8):1207-1212.
4. Brahmajothi M.V., Campbell D.L. Heterogeneous basal expression of nitric oxide synthase and superoxide dismutase isoforms in mammalian heart: implications for mechanisms governing indirect and direct nitric oxide-related effects. Circ. Res. 1999, 85(7):575-587.
5. Brunner F., Maier R., Andrew P., Wolkart G., Zechner R., Mayer B. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Cardiovasc. Res. 2003, 57(1):55-62.
6. Chen H., Montagnani M., Funahashi T., Shimomura I., Quon M.J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J. Biol. Chem. 2003, 278(45):45021-45026.
7. Chen Z., Peng I.C., Sun W., Su M.I., Hsu P.H., Fu Y., Zhu Y., DeFea K., Pan S., Tsai M.D., Shyy J.Y. AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ. Res. 2009, 104(4):496-505.
8. Cheng Y.T., Yang Y.J., Zhang H.T., Qian H.Y., Zhao J.L., Meng X.M., Luo F.L., Wu Y.L. Pretreatment with Tongxinluo protects porcine myocardium from ischaemia/reperfusion injury through a nitric oxide related mechanism. Chin. Med. J. (Engl) 2009, 122(13):1529-1538.
9. Davies S.P., Reddy H., Caivano M., Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351(Pt 1):95-105.
10. du Toit E.F., McCarthy J., Miyashiro J., Opie L.H., Brunner F. Effect of nitrovasodilators and inhibitors of nitric oxide synthase on ischaemic and reperfusion function of rat isolated hearts. Br. J. Pharmacol. 1998, 123(6):1159-1167.
11. Giraldez R.R., Panda A., Xia Y., Sanders S.P., Zweier J.L. Decreased nitric-oxide synthase activity causes impaired endothelium-dependent relaxation in the postischemic heart. J. Biol. Chem. 1997, 272(34):21420-21426.
12. Harris M.B., Blackstone M.A., Sood S.G., Li C., Goolsby J.M., Venema V.J., Kemp B.E., Venema R.C. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H560-H566.
13. Hashimoto A., Miyakoda G., Hirose Y., Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006, 189(2):350-357.
14. Hausenloy D.J., Yellon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc. Res. 2006, 70(2):240-253.
15. Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev. 2007, 12(3-4):217-234.
16. Inserte J., Garcia-Dorado D., Ruiz-Meana M., Agullo L., Pina P., Soler-Soler J. Ischemic preconditioning attenuates calpain-mediated degradation of structural proteins through a protein kinase A-dependent mechanism. Cardiovasc. Res. 2004, 64(1):105-114.
17. Jaffe R., Charron T., Puley G., Dick A., Strauss B.H. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 2008, 117(24):3152-3156.
18. Jobgen W.S., Fried S.K., Fu W.J., Meininger C.J., Wu G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J. Nutr. Biochem. 2006, 17(9):571-588.
19. Jones S.P., Girod W.G., Palazzo A.J., Granger D.N., Grisham M.B., Jourd'Heuil D., Huang P.L., Lefer D.J. Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am. J. Physiol. 1999, 276(5 Pt 2):H1567-H1573.
20. Jones S.P., Greer J.J., Kakkar A.K., Ware P.D., Turnage R.H., Hicks M., van Haperen R., de Crom R., Kawashima S., Yokoyama M., Lefer D.J. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2004, 286(1):H276-H282.
21. Jugdutt B.I. Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev. 2002, 7(4):391-405.
22. Kanno S., Lee P.C., Zhang Y., Ho C., Griffith B.P., Shears L.L., Billiar T.R. Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation 2000, 101(23):2742-2748.
23. Li X.D., Yang Y.J., Geng Y.J., Jin C., Hu F.H., Zhao J.L., Zhang H.T., Cheng Y.T., Qian H.Y., Wang L.L., Zhang B.J., Wu Y.L. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am. J. Physiol. Heart Circ. Physiol. 2010, 299(4):H1255-H1261.
24. Lochner A., Genade S., Tromp E., Podzuweit T., Moolman J.A. Ischemic preconditioning and the beta-adrenergic signal transduction pathway. Circulation 1999, 100(9):958-966.
25. Makaula S., Lochner A., Genade S., Sack M.N., Awan M.M., Opie L.H. H-89, a non-specific inhibitor of protein kinase A, promotes post-ischemic cardiac contractile recovery and reduces infarct size. J. Cardiovasc. Pharmacol. 2005, 45(4):341-347.
26. Mallet R.T., Ryou M.G., Williams A.G., Howard L., Downey H.F. Beta1-Adrenergic receptor antagonism abrogates cardioprotective effects of intermittent hypoxia. Basic Res. Cardiol. 2006, 101(5):436-446.
27. Manganello J.M., Huang J.S., Kozasa T., Voyno-Yasenetskaya T.A., Le Breton G.C. Protein kinase A-mediated phosphorylation of the Galpha13 switch I region alters the Galphabetagamma13-G protein-coupled receptor complex and inhibits Rho activation. J. Biol. Chem. 2003, 278(1):124-130.
28. Mei F.C., Qiao J., Tsygankova O.M., Meinkoth J.L., Quilliam L.A., Cheng X. Differential signaling of cyclic AMP: opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation. J. Biol. Chem. 2002, 277(13):11497-11504.
29. Michel T., Vanhoutte P.M. Cellular signaling and NO production. Pflugers Arch 2010, 459(6):807-816.
30. Mount P.F., Kemp B.E., Power D.A. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell. Cardiol. 2007, 42(2):271-279.
31. Muscari C., Bonafe F., Gamberini C., Giordano E., Tantini B., Fattori M., Guarnieri C., Caldarera C.M. Early preconditioning prevents the loss of endothelial nitric oxide synthase and enhances its activity in the ischemic/reperfused rat heart. Life Sci. 2004, 74(9):1127-1137.
32. Nomura Y., Horimoto H., Mieno S., Nakahara K., Okawa H., Yoshida M., Shinjiro S. Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction. Mol. Cell. Biochem. 2003, 248(1-2):179-184.
33. Recchia F.A., Osorio J.C., Chandler M.P., Xu X., Panchal A.R., Lopaschuk G.D., Hintze T.H., Stanley W.C. Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 2002, 282(1):E197-E206.
34. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ. Res. 2005, 97(12):1232-1235.
35. Robinet A., Hoizey G., Millart H. PI 3-kinase, protein kinase C, and protein kinase A are involved in the trigger phase of beta1-adrenergic preconditioning. Cardiovasc. Res. 2005, 66(3):530-542.
36. Rodrigues S.F., Granger D.N. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. Cardiovasc. Res. 2010, 87(2):291-299.
37. Sanada S., Kitakaze M., Papst P.J., Asanuma H., Node K., Takashima S., Asakura M., Ogita H., Liao Y., Sakata Y., Ogai A., Fukushima T., Yamada J., Shinozaki Y., Kuzuya T., Mori H., Terada N., Hori M. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 2001, 104(6):705-710.
38. Sanada S., Asanuma H., Tsukamoto O., Minamino T., Node K., Takashima S., Fukushima T., Ogai A., Shinozaki Y., Fujita M., Hirata A., Okuda H., Shimokawa H., Tomoike H., Hori M., Kitakaze M. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004, 110(1):51-57.
39. Shimokawa H., Seto M., Katsumata N., Amano M., Kozai T., Yamawaki T., Kuwata K., Kandabashi T., Egashira K., Ikegaki I., Asano T., Kaibuchi K., Takeshita A. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 1999, 43(4):1029-1039.
40. Soria L.R., Gradilone S.A., Larocca M.C., Marinelli R.A. Glucagon induces the gene expression of aquaporin-8 but not that of aquaporin-9 water channels in the rat hepatocyte. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296(4):R1274-R1281.
41. Stankunas K., Ma G.K., Kuhnert F.J., Kuo C.J., Chang C.P. VEGF signaling has distinct spatiotemporal roles during heart valve development. Dev. Biol. 2010, 347(2):325-336.
42. Verma S., Fedak P.W., Weisel R.D., Butany J., Rao V., Maitland A., Li R.K., Dhillon B., Yau T.M. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002, 105(20):2332-2336.
43. Williams J.G., Ojaimi C., Qanud K., Zhang S., Xu X., Recchia F.A., Hintze T.H. Coronary nitric oxide production controls cardiac substrate metabolism during pregnancy in the dog. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(6):H2516-H2523.
44. Xi L., Jarrett N.C., Hess M.L., Kukreja R.C. Essential role of inducible nitric oxide synthase in monophosphoryl lipid A-induced late cardioprotection: evidence from pharmacological inhibition and gene knockout mice. Circulation 1999, 99(16):2157-2163.
45. Xuan Y.T., Guo Y., Zhu Y., Wang O.L., Rokosh G., Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 2007, 116(5):535-544.
46. Yang X., Cohen M.V., Downey J.M. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther. 2010, 24(3):225-234.
47. Zaccolo M. Phosphodiesterases and compartmentalized cAMP signalling in the heart. Eur. J. Cell Biol. 2006, 85(7):693-697.
48. Zhang X.P., Hintze T.H. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 2006, 290(6):H2376-H2384.
49. Zhao Z.Q., Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc. Res. 2006, 70(2):200-211.
50. Zhao J.L., Yang Y.J., Cui C.J., You S.J., Gao R.L. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial K(ATP) channel. Br. J. Pharmacol. 2006, 149(3):243-249.